SCANDARE: an institutional dynamic prospective interventional biobanking study

We set up a prospective longitudinal biobanking study answering scientific questions within a regulatory framework and patient-centered approach. We aim in this paper to present the opportunities of such a study, as well as the challenges and the limitations. SCANDARE (NCT03017573) is an institutional first monocentric then multicentric biobanking study. The study enrolled adult patients with newly diagnosed head and neck squamous cell carcinoma, triple negative breast cancer, ovarian and cervical cancer. All patients signed a consent form before any procedure. Tumor tissue and blood samples are collected at several time points during patient's journey, including at diagnosis, post-neoadjuvant chemotherapy in case of neoadjuvant treatment, at surgery, at recurrence and at disease progression following treatment initiated at recurrence. Clinical data are entered into an eCRF, whereas generated data are centralized in a secure database. SCANDARE started in 2017 at Institut Curie and has included 676 patients at date. SCANDARE successfully addressed challenges related to patient consent, regulatory compliance, and logistical integration of sample collection into routine clinical practice. The study facilitated the longitudinal collection and preservation of tumor and blood samples, enabling comprehensive analyses from histopathology to genomics and proteomics needed for the 35 ongoing projects run by academic research groups and industry. The implementation of optimized sampling and data workflows enabled high-quality data. Several other cohorts are planned to open soon. SCANDARE is an institutional, prospective and dynamic biobanking study that successfully enabled the implementation of 35 research projects with clinical and omics data centralized in a secure database available for all collaborators on demand. Looking ahead, SCANDARE aims to expand its scope by including additional cancer types and patient cohorts, further enhancing the potential for translational research and personalized medicine in oncology.